Loading...
SLU-PP-322
Add to Wishlist
EPO Receptor Modulator for Neuroprotection Without Erythropoiesis
In Stock
5mg
$80.00$96.00
You Save
$16.00In Stock — Ships Same Day
Includes
5mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
SLU-PP-322 is a small molecule non-erythropoietic erythropoietin (EPO) receptor modulator developed at Saint Louis University that selectively activates the tissue-protective signaling arm of the EPO receptor (EPOR) heterodimer without engaging the classical homodimeric EPOR pathway responsible for erythropoiesis. At the molecular level, SLU-PP-322 is proposed to preferentially signal through the EPOR/beta common receptor (betacR) heterodimer complex, activating the JAK2-STAT5 and PI3K/Akt neuroprotective cascades that promote neuronal survival, anti-apoptotic gene expression, and anti-inflammatory cytokine profiles while avoiding the EPOR homodimer-mediated stimulation of red blood cell production that causes dangerous polycythemia and thromboembolic complications with traditional EPO use. Published peer-reviewed research demonstrates that EPO receptor tissue-protective signaling is distinct from its hematopoietic function, and non-erythropoietic EPOR modulators have been investigated in preclinical models of ischemic stroke, traumatic brain injury, peripheral neuropathy, and spinal cord injury with reports of reduced infarct volume, preserved neurological function, and decreased inflammatory infiltration. What distinguishes SLU-PP-322 from carbamylated EPO (CEPO) and other non-erythropoietic EPO derivatives is its small molecule format, which offers potential advantages in blood-brain barrier penetration, oral bioavailability, manufacturing scalability, and consistent pharmacokinetic properties compared to large recombinant protein-based approaches. Current scientific investigation focuses on optimizing EPOR/betacR selectivity, characterizing neuroprotective dose-response relationships, and exploring applications in neurodegenerative disease models where chronic neuroinflammation and neuronal loss are central pathological features.
Handling & Storage
Published research protocols reference daily subcutaneous administration. Store at -20°C until reconstitution. Consult applicable literature for specific research applications.
Published Research Protocols
Published research protocols reference protocol-dependent dosing. Consult applicable literature for specific research applications.
Research Applications
Neuroprotection
SLU-PP-322 activates the tissue-protective EPOR/betacR heterodimer signaling pathway, engaging JAK2-STAT5 and PI3K/Akt cascades that upregulate anti-apoptotic proteins (Bcl-2, Bcl-xL), inhibit caspase-3 activation, and promote neuronal survival under conditions of ischemia, excitotoxicity, and oxidative stress. Published preclinical research on non-erythropoietic EPO receptor modulators demonstrates significant reductions in infarct volume and preserved neurological function scores in stroke and traumatic brain injury models.
Initial effects within first month
Anti-Inflammatory
Non-erythropoietic EPOR signaling through the betacR heterodimer suppresses NF-kB-mediated pro-inflammatory gene transcription, reduces microglial activation and astrocyte reactivity, and attenuates the production of inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) that drive secondary neuronal damage following acute brain injury. Published research suggests this anti-inflammatory mechanism also modulates chronic neuroinflammation implicated in neurodegenerative conditions including Alzheimer's and Parkinson's disease pathology.
Initial effects within first month
Cognitive Support
By promoting neuronal survival, reducing neuroinflammation, and supporting neurovascular unit integrity without altering red blood cell counts or blood viscosity, SLU-PP-322 maintains the neural substrate for cognitive function. Published research on tissue-protective EPOR signaling demonstrates preserved hippocampal neuronal density, maintained synaptic protein expression, and improved performance on memory and learning tasks in preclinical models of acute and chronic brain injury.
Initial effects within first month
Frequently Asked Questions
How should this peptide be stored?
SLU-PP-322 in lyophilized form should be stored at -20°C for long-term stability, where it remains viable for up to 24 months. As a small molecule rather than a peptide, SLU-PP-322 has inherent chemical stability advantages. Once reconstituted with an appropriate solvent, store at 2-8°C and use within 30 days. Protect from light and moisture during both storage and handling.
What quality controls are in place?
Every SLU-PP-322 batch is independently tested by Janoshik Analytical Laboratory using HPLC for purity (99%+) and mass spectrometry for molecular identity confirmation. As a novel EPO receptor modulator, identity verification is particularly important to confirm the specific structural features responsible for EPOR/betacR heterodimer selectivity over classical EPOR homodimer activation. Sterility and endotoxin testing are performed on each batch.
Can I see the Certificate of Analysis?
Yes, Certificates of Analysis documenting HPLC purity, mass spectrometry identity, and sterility testing are available for every SLU-PP-322 batch. You can find them on the product page under the Lab Results section, or contact support@pepcelllabs.com for specific batch documentation.
What is the shelf life after reconstitution?
Once reconstituted, SLU-PP-322 should be stored at 2-8°C protected from light and used within 28-30 days. As a small molecule compound, it generally maintains stability better than larger peptides in aqueous solution, but freshly prepared solutions are recommended for research protocols requiring precise dose-response characterization.
Is this product for human use?
SLU-PP-322 is sold strictly for in-vitro research, laboratory use, and educational purposes. This is an early-stage research compound developed at Saint Louis University with no human clinical trials conducted or planned at this time. The broader field of non-erythropoietic EPO receptor modulators is in preclinical development. This product is not intended for human consumption or self-administration. Always consult applicable regulations in your jurisdiction.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Research Articles
Published research and educational content related to SLU-PP-322
Research11 min read
BPC-157 vs TB-500: Comparing Recovery Research Peptides
A detailed comparison of two of the most studied recovery peptides in preclinical research, examining their distinct mechanisms, published findings, and how investigators approach studying them individually and in combination.
Dr. Sarah ChenChief Science Officer
Research12 min read
Growth Hormone Secretagogues: CJC-1295, Ipamorelin, GHRP-2 & GHRP-6 Research Overview
A comprehensive research overview of the major growth hormone secretagogues, including GHRH analogs and ghrelin receptor agonists, their mechanisms of action, selectivity profiles, and published preclinical and clinical findings.
Dr. James ParkResearch Analyst
Research14 min read
Immune-Modulating Peptides: Thymosin Alpha-1, LL-37, and KPV Research
An overview of three key peptides being studied for their immune-modulating properties, covering innate and adaptive immune mechanisms, published research findings, and the current state of immunopeptide science.
Michael TorresContent Director
Research13 min read
Longevity Peptides: Epithalon, NAD+, MOTS-c & Cellular Aging Research
An exploration of the leading peptides and peptide-related compounds being studied in cellular aging research, from telomere biology and Epithalon to mitochondrial-targeted peptides and NAD+ precursors.
Dr. Sarah ChenChief Science Officer
